Blake learns to live with cancer
28 Mar 2008 | : *News*
Dan Rosen | NHL.com Staff Writer
Mar 27, 2008, 9:00 AM EDT
 |
Jason Blake has persevered while dealing with cancer and a new team.  Blake video |
The word sliced through Jason Blake like a sharp knife.
Cancer.
“Anyone that hears the word … the first thing they think is, ‘Oh crap, this is it,’ ” Blake said.
Blake already was going through a major life change, uprooting his wife and three kids from comfortable Long Island and moving to bustling Toronto, going from the relatively quiet scene around the Islanders and Nassau Coliseum to the media-dominated Maple Leafs. He already had to adapt to new coaches, new teammates, new systems, new fans, new everything.
Now he had to do it all while battling cancer, too?
If it ever has been too much to handle, only Blake or his New York-based sports therapist know. Even through what he calls the most difficult year of his life, Blake has persevered, which is why he is the Toronto chapter of the Professional Hockey Writers’ Association’s nominee for the Bill Masterton Memorial Trophy.
“It is hard mentally – it would be on anybody – but he never brings it up at the rink,” linemate Matt Stajan told the Toronto Sun. “He has handled it so well. He is always upbeat and hyper. That’s just his personality. You would never know he has it.
“He is deserving of (recognition for the Masterton). He has gone on with his life.”
Thanks to a little pill called Gleevac, which Blake takes every morning with his breakfast, he has been able to play in every game this season.
He hasn’t put up stunning numbers and the Leafs haven’t exactly set the NHL ablaze with their play, but the fact that Blake is living a normal life and still playing at the highest possible level are two victories that mean a heck of a lot more than four points.
“The first day I found out, (my doctor) told me that as long as you stay on the pill … you’ll be fine,” Blake said. “As time went on and as the hockey season has gone forward, to be honest with you, I forget about it. I really do. I have to take a pill every day, but I just think of it that I have to take my vitamins.”
Blake said he regularly takes a drug called Immunocal, which is made for cancer patients and is supposed to help keep weight on. Gleevac caused him to lose eight pounds, but Immunocal makes sure he doesn’t lose anymore.
“That was expected when I started the medicine, but I’m getting it back” Blake said. “We had to experiment to find the best thing for me to take to build the weight back up. Michael Peca suggested (Immunocal) to me.”
Blake is thankful for all of the medication, even the diagnosis.
He said the cancer likely was forming in his body for at least two years, and he used to feel rundown. Since starting the medication he said he feels great, and his energy level is through the roof.
“The medicine brings everything back to normal,” Blake said. “It doesn’t matter if you’re an athlete or just an every-day guy, you perform better when everything in your body is correct. That’s what this pill does. It makes sure everything is balanced.
“People always ask me, ‘How do you feel?’ To be honest, I feel better than ever.”
He’s talking in a physical sense.
Blake confessed that mentally he’s drained, but that has less to do with the cancer and more to do with how his hockey season has gone.
After scoring 40 goals last season and averaging more than 28 in each of the last four seasons, Blake had scored 15 times this season through Tuesday. The Leafs, meanwhile, were 12th in the Eastern Conference, six points out of a playoff spot with only five games to play.
Blake admits he just hasn’t had a great deal of fun.
“I was an All-Star last year, but it’s almost like that’s what you were on Long Island, but when you come to a new team you’re a nobody,” he said. “You have to start over and make a name for yourself. I think anyone that goes through transition – it’s not as easy as what people think. I’m a goal scorer, and if you’re not scoring goals and winning, how can it be a fun year?”
“If I do get through it,” Blake continued, “I’ll look back and ask, ‘How the heck did I get through that?’ ”
One reason is Blake’s semi-daily conversations with his sports therapist.
“We talk quite a bit actually, probably every other day,” Blake said. “This has been the worst season offensively for me, and obviously you’re on tilt everyday wondering why this isn’t happening if it hasn’t happened the last couple of years. He tries to settle me down, calm my nerves and put good thoughts in my head. He’s someone that is not going to just tell me what I want to hear.”
More than five months ago, a different doctor gave Blake the honest truth, the morbid truth. He didn’t want to hear the word cancer at that time, but Blake has done the only thing he knows how to do.
Adapt and move on.
“I don’t know if I’ll be here next year, I just know personally I’ll never have a season like this again,” Blake said. “I don’t know if it can get any more difficult than this.
“It’s been a tough year, (so when it’s over) I’ll feel like I’ve overcome.”
Contact Dan Rosen at drosen@nhl.com.
Masterton Trophy
The Bill Masterton Memorial Trophy is an annual award under the trusteeship of the Professional Hockey Writers’ Association and is given to the NHL player who best exemplifies the qualities of perseverance, sportsmanship, and dedication to hockey. The winner is selected in a poll of all chapters of the PHWA at the end of the regular season.
A grant from the PHWA is awarded annually to the Bill Masterton Scholarship Fund, based in Bloomington, Minn., in the name of the Masterton Trophy winner.
The trophy was first presented by the NHL Writers’ Association in 1968 to commemorate the late William Masterton, a player for the Minnesota North Stars, who exhibited, to a high degree, the qualities of perseverance, sportsmanship and dedication to hockey. Masterton died on Jan. 15, 1968, after an injury sustained during a hockey game.
Living with Meso - Charlene’s story
26 Mar 2008 | : Announcements
Charlene Kaforey, 48, had been troubled by stomach problems for almost four years. She and her doctors tried a variety of things to determine the cause, settling on a tentative diagnosis of Crohn’s Disease. But none of the medications typically used to treat Crohn’s had any effect on Charlene’s condition.
Frustrated, in the fall of 2006 she tried a new medication for a two-week protocol, plus a gluten-free diet for six months, and finally experienced some relief. But then, six months later, the pain and discomfort returned.
Since she had been off Crohn’s medications during the experiment with her diet, doctors decided it would be a good time to try some new tests, and included a CT scan. In March 2007, tests showed nothing wrong with Charlene’s stomach, but something odd at the base of her left lung. The doctor conducting the scan didn’t think it was anything serious, but recommended that she follow up with her primary care physician anyway.
In May 2007, Charlene received a chest CT scan, which revealed three spots on her left lung. Doctors suspected lymphoma. A cardio-thoracic specialist followed up with a PET scan, which showed the same three spots. He recommended a “wait and see” approach, suggesting they could check the area again in three to six months.
“I didn’t want to wait,” Charlene said.
At her request, doctors did a lung biopsy in July, and she was told she has mesothelioma.
Please be sure to visit www.mymeso.org
Skin Cancer Risk Factor: Where You Live
25 Mar 2008 | : *News*
|
|
|||||
|
|||||
Did you know that many men will have advanced prostate cancer without any noticeable symptoms? Pennies For Patients 2008
18 Mar 2008 | : Announcements, Events
The 2008 Pennies for Patients campaign is about to begin!
Pennies for Patients® is a fun and educational community service project in which area students collect and donate their spare change to The Leukemia & Lymphoma Society. The community service project runs for three weeks during February (or any 3-week period that works best for you).
We invite you to participate in 2007-2008!
Pennies, nickles, dimes and quarters add up to dollars that can help The Leukemia & Lymphoma Society® find a cure for leukemia, lymphoma, Hodgkin’s disease and myeloma, and to improve the quality of life of patients and their families.
Last year, 270 area schools and 120,000 students worked together to raise an amazing $209,000 for The Leukemia & Lymphoma Society. In 2008, we expect over 400 schools to raised $280,000 - from students and pennies alone! That’s 28 million pennies!
Clinical Cancer Research
17 Mar 2008 | : *News*
A new issue of Clinical Cancer Research is available online:
15 March 2008; Vol. 14, No. 6
The below Table of Contents is available online at: http://clincancerres.aacrjournals.org/content/vol14/issue6/?etoc
——————————————————————————–
CCR Practice of Translational Oncology
——————————————————————————–
Understanding the Biology of Bone Metastases: Key to the Effective Treatment of Prostate Cancer
Christopher J. Logothetis, Nora M. Navone, and Sue-Hwa Lin
Clin Cancer Res 2008;14 1599-1602
http://clincancerres.aacrjournals.org/cgi/content/abstract/14/6/1599
——————————————————————————–
Molecular Pathways
——————————————————————————–
Capitalizing on the Immunogenicity of Dying Tumor Cells
Catia Fonseca and Glenn Dranoff
Clin Cancer Res 2008;14 1603-1608
http://clincancerres.aacrjournals.org/cgi/content/abstract/14/6/1603
——————————————————————————–
Focus Section
——————————————————————————–
Newer Cytotoxic Agents: Attacking Cancer Broadly
Beverly A. Teicher
Clin Cancer Res 2008;14 1610-1617
http://clincancerres.aacrjournals.org/cgi/content/abstract/14/6/1610
The Epothilones: Translating from the Laboratory to the Clinic
James J. Lee and Sandra M. Swain
Clin Cancer Res 2008;14 1618-1624
http://clincancerres.aacrjournals.org/cgi/content/abstract/14/6/1618
Vinflunine: A New Microtubule Inhibitor Agent
Jaafar Bennouna, Jean-Pierre Delord, Mario Campone, and Laurent Nguyen
Clin Cancer Res 2008;14 1625-1632
http://clincancerres.aacrjournals.org/cgi/content/abstract/14/6/1625
Current Status and Future Prospects for Satraplatin, an Oral Platinum Analogue
Hak Choy, Clinton Park, and Min Yao
Clin Cancer Res 2008;14 1633-1638
http://clincancerres.aacrjournals.org/cgi/content/abstract/14/6/1633
Aurora Kinases as Anticancer Drug Targets
Oliver Gautschi, Jim Heighway, Philip C. Mack, Phillip R. Purnell, Primo N. Lara, Jr., and David R. Gandara
Clin Cancer Res 2008;14 1639-1648
http://clincancerres.aacrjournals.org/cgi/content/abstract/14/6/1639
Proteasome Inhibitors in Cancer Therapy: Lessons from the First Decade
Robert Z. Orlowski and Deborah J. Kuhn
Clin Cancer Res 2008;14 1649-1657
http://clincancerres.aacrjournals.org/cgi/content/abstract/14/6/1649
——————————————————————————–
Human Cancer Biology
——————————————————————————–
Small Molecular Weight Variants of p53 Are Expressed in Human Melanoma Cells and Are Induced by the DNA-Damaging Agent Cisplatin
Kelly A. Avery-Kiejda, Xu Dong Zhang, Luke J. Adams, Rodney J. Scott, Borivoj Vojtesek, David P. Lane, and Peter Hersey
Clin Cancer Res 2008;14 1659-1668
http://clincancerres.aacrjournals.org/cgi/content/abstract/14/6/1659
Class I Histone Deacetylase Expression Has Independent Prognostic Impact in Human Colorectal Cancer: Specific Role of Class I Histone Deacetylases In vitro and In vivo
Wilko Weichert, Annika Röske, Silvia Niesporek, Aurelia Noske, Ann-Christin Buckendahl, Manfred Dietel, Volker Gekeler, Markus Boehm, Thomas Beckers, and Carsten Denkert
Clin Cancer Res 2008;14 1669-1677
http://clincancerres.aacrjournals.org/cgi/content/abstract/14/6/1669
Endothelial Differentiation of Hematopoietic Stem and Progenitor Cells from Patients with Multiple Myeloma
Roberto Ria, Claudia Piccoli, Teresa Cirulli, Franca Falzetti, Giuseppe Mangialardi, Diego Guidolin, Antonio Tabilio, Nicola Di Renzo, Attilio Guarini, Domenico Ribatti, Franco Dammacco, and Angelo Vacca
Clin Cancer Res 2008;14 1678-1685
http://clincancerres.aacrjournals.org/cgi/content/abstract/14/6/1678
Expression of the Bric-a-Brac Tramtrack Broad Complex Protein NAC-1 in Cervical Carcinomas Seems to Correlate with Poorer Prognosis
Shamima Yeasmin, Kentaro Nakayama, Masako Ishibashi, Atsuko Katagiri, Kouji Iida, Indri Nuryani Purwana, Naomi Nakayama, and Kohji Miyazaki
Clin Cancer Res 2008;14 1686-1691
http://clincancerres.aacrjournals.org/cgi/content/abstract/14/6/1686
——————————————————————————–
Imaging, Diagnosis, Prognosis
——————————————————————————–
Molecular, Pathologic, and Clinical Features of Early-Onset Endometrial Cancer: Identifying Presumptive Lynch Syndrome Patients
Michael D. Walsh, Margaret C. Cummings, Daniel D. Buchanan, Wendy M. Dambacher, Sven Arnold, Diane McKeone, Rebecca Byrnes, Melissa A. Barker, Barbara A. Leggett, Michael Gattas, Jeremy R. Jass, Amanda B. Spurdle, Joanne Young, and Andreas Obermair
Clin Cancer Res 2008;14 1692-1700
http://clincancerres.aacrjournals.org/cgi/content/abstract/14/6/1692
IMP3 Predicts Aggressive Superficial Urothelial Carcinoma of the Bladder
Lioudmila Sitnikova, Gary Mendese, Qin Liu, Bruce A. Woda, Di Lu, Karen Dresser, Sambit Mohanty, Kenneth L. Rock, and Zhong Jiang
Clin Cancer Res 2008;14 1701-1706
http://clincancerres.aacrjournals.org/cgi/content/abstract/14/6/1701
Pfetin as a Prognostic Biomarker of Gastrointestinal Stromal Tumors Revealed by Proteomics
Yoshiyuki Suehara, Tadashi Kondo, Kunihiko Seki, Tatsuhiro Shibata, Kiyonaga Fujii, Masahiro Gotoh, Tadashi Hasegawa, Yasuhiro Shimada, Mitsuru Sasako, Tadakazu Shimoda, Hisashi Kurosawa, Yasuo Beppu, Akira Kawai, and Setsuo Hirohashi
Clin Cancer Res 2008;14 1707-1717
http://clincancerres.aacrjournals.org/cgi/content/abstract/14/6/1707
Prognostic Value of Body Mass Index in Locally Advanced Breast Cancer
Shaheenah Dawood, Kristine Broglio, Ana M. Gonzalez-Angulo, Shu-Wan Kau, Rabiul Islam, Gabriel N. Hortobagyi, and Massimo Cristofanilli
Clin Cancer Res 2008;14 1718-1725
http://clincancerres.aacrjournals.org/cgi/content/abstract/14/6/1718
Subcellular Localization of Activated Leukocyte Cell Adhesion Molecule Is a Molecular Predictor of Survival in Ovarian Carcinoma Patients
Delia Mezzanzanica, Marina Fabbi, Marina Bagnoli, Samantha Staurengo, Marco Losa, Emanuela Balladore, Paola Alberti, Lara Lusa, Antonino Ditto, Silvano Ferrini, Marco A. Pierotti, Mattia Barbareschi, Silvana Pilotti, and Silvana Canevari
Clin Cancer Res 2008;14 1726-1733
http://clincancerres.aacrjournals.org/cgi/content/abstract/14/6/1726
Identification of Prognostic Biomarkers for Prostate Cancer
Farhad Kosari, Jan Marie A. Munz, C. Dilara Savci-Heijink, Craig Spiro, Eric W. Klee, Dagmar Marie Kube, Lori Tillmans, Jeff Slezak, R. Jeffrey Karnes, John C. Cheville, and George Vasmatzis
Clin Cancer Res 2008;14 1734-1743
http://clincancerres.aacrjournals.org/cgi/content/abstract/14/6/1734
A Gene Expression Signature that Can Predict the Recurrence of Tamoxifen-Treated Primary Breast Cancer
Maïa Chanrion, Vincent Negre, Hélène Fontaine, Nicolas Salvetat, Frédéric Bibeau, Gaëtan Mac Grogan, Louis Mauriac, Dionyssios Katsaros, Franck Molina, Charles Theillet, and Jean-Marie Darbon
Clin Cancer Res 2008;14 1744-1752
http://clincancerres.aacrjournals.org/cgi/content/abstract/14/6/1744
Overall and Relapse-Free Survival in Oropharyngeal and Hypopharyngeal Squamous Cell Carcinoma Are Associated with Genotypes of T393C Polymorphism of the GNAS1 Gene
Goetz F. Lehnerdt, Peter Franz, Anwar Zaqoul, Klaus J. Schmitz, Sara Grehl, Stephan Lang, Kurt W. Schmid, Winfried Siffert, Klaus Jahnke, and Ulrich H. Frey
Clin Cancer Res 2008;14 1753-1758
http://clincancerres.aacrjournals.org/cgi/content/abstract/14/6/1753
Topoisomerase II Expression as an Independent Prognostic Factor in Hodgkin’s Lymphoma
Ipatia A. Doussis-Anagnostopoulou, Theodoros P. Vassilakopoulos, Irini Thymara, Penelope Korkolopoulou, Maria K. Angelopoulou, Marina P. Siakantaris, Styliani I. Kokoris, Evangelia M. Dimitriadou, Christina Kalpadakis, Marina Matzouranis, Loukas Kaklamanis, Panayiotis Panayiotidis, Marie-Christine Kyrtsonis, Athina Androulaki, Efstratios Patsouris, Christos Kittas, and Gerassimos A. Pangalis
Clin Cancer Res 2008;14 1759-1766
http://clincancerres.aacrjournals.org/cgi/content/abstract/14/6/1759
Cyclin D1 Expression in Breast Cancer Patients Receiving Adjuvant Tamoxifen-Based Therapy
Margaretha Rudas, Martina Lehnert, Anh Huynh, Raimund Jakesz, Christian Singer, Sigurd Lax, Walter Schippinger, Otto Dietze, Richard Greil, Wolfgang Stiglbauer, Werner Kwasny, Renate Grill, Michael Stierer, Michael F.X. Gnant, Martin Filipits for the Austrian Breast and Colorectal Cancer Study Group
Clin Cancer Res 2008;14 1767-1774
http://clincancerres.aacrjournals.org/cgi/content/abstract/14/6/1767
Prognostic Factors in Renal Cell Carcinoma: Association of Preoperative Sodium Concentration with Survival
Naveen S. Vasudev, Janet E. Brown, Sarah R. Brown, Rumana Rafiq, Ruth Morgan, Poulam M. Patel, Dearbhaile O’Donnell, Patricia Harnden, Mark Rogers, Kim Cocks, Kirsty Anderson, Alan Paul, Ian Eardley, Peter J. Selby, and Rosamonde E. Banks
Clin Cancer Res 2008;14 1775-1781
http://clincancerres.aacrjournals.org/cgi/content/abstract/14/6/1775
——————————————————————————–
Cancer Therapy: Clinical
——————————————————————————–
Improving the Quality of Abstract Reporting for Phase I Cancer Trials
Elizabeth L. Strevel, Nicole G. Chau, Gregory R. Pond, Anthony J. Murgo, Percy S. Ivy, and Lillian L. Siu
Clin Cancer Res 2008;14 1782-1787
http://clincancerres.aacrjournals.org/cgi/content/abstract/14/6/1782
Irinotecan Pharmacogenetics: Influence of Pharmacodynamic Genes
Janelle M. Hoskins, Eugenio Marcuello, Albert Altes, Sharon Marsh, Taylor Maxwell, Derek J. Van Booven, Laia Paré, Robert Culverhouse, Howard L. McLeod, and Montserrat Baiget
Clin Cancer Res 2008;14 1788-1796
http://clincancerres.aacrjournals.org/cgi/content/abstract/14/6/1788
Correlation of CDA, ERCC1, and XPD Polymorphisms with Response and Survival in Gemcitabine/Cisplatin–Treated Advanced Non–Small Cell Lung Cancer Patients
Carmelo Tibaldi, Elisa Giovannetti, Enrico Vasile, Valentina Mey, Adrie C. Laan, Sara Nannizzi, Roberta Di Marsico, Andrea Antonuzzo, Cinzia Orlandini, Simona Ricciardi, Mario Del Tacca, Godefridus J. Peters, Alfredo Falcone, and Romano Danesi
Clin Cancer Res 2008;14 1797-1803
http://clincancerres.aacrjournals.org/cgi/content/abstract/14/6/1797
——————————————————————————–
Cancer Therapy: Preclinical
——————————————————————————–
Targeting Hyaluronan Interactions in Malignant Gliomas and Their Drug-Resistant Multipotent Progenitors
Anne G. Gilg, Sandra L. Tye, Lauren B. Tolliver, William G. Wheeler, Richard P. Visconti, James D. Duncan, Felina V. Kostova, Letitia N. Bolds, Bryan P. Toole, and Bernard L. Maria
Clin Cancer Res 2008;14 1804-1813
http://clincancerres.aacrjournals.org/cgi/content/abstract/14/6/1804
Antimyeloma Effects of a Sesquiterpene Lactone Parthenolide
Attaya Suvannasankha, Colin D. Crean, Rajasubramaniam Shanmugam, Sherif S. Farag, Rafat Abonour, H. Scott Boswell, and Harikrishna Nakshatri
Clin Cancer Res 2008;14 1814-1822
http://clincancerres.aacrjournals.org/cgi/content/abstract/14/6/1814
Cytotoxicity and Proteomics Analyses of OSU03013 in Lung Cancer
Yi-Hung Tan, Kung-Hsueh Lee, Topp Lin, Ying-Chieh Sun, Hsiu Mei Hsieh-Li, Hsueh-Fen Juan, and Yi-Ching Wang
Clin Cancer Res 2008;14 1823-1830
http://clincancerres.aacrjournals.org/cgi/content/abstract/14/6/1823
Synergistic Antipancreatic Tumor Effect by Simultaneously Targeting Hypoxic Cancer Cells With HSP90 Inhibitor and Glycolysis Inhibitor
Xianhua Cao, Mark Bloomston, Tao Zhang, Wendy L. Frankel, Guang Jia, Bing Wang, Nathan C. Hall, Regina M. Koch, Hao Cheng, Michael V. Knopp, and Duxin Sun
Clin Cancer Res 2008;14 1831-1839
http://clincancerres.aacrjournals.org/cgi/content/abstract/14/6/1831
Vitamin E Succinate Induces Ceramide-Mediated Apoptosis in Head and Neck Squamous Cell Carcinoma In vitro and In vivo
Xinbin Gu, Xiaodong Song, Yongheng Dong, Hui Cai, Eric Walters, Renshu Zhang, Xiaowu Pang, Tianpei Xie, Yinhan Guo, Rajagopalan Sridhar, and Joseph A. Califano
Clin Cancer Res 2008;14 1840-1848
http://clincancerres.aacrjournals.org/cgi/content/abstract/14/6/1840
Resveratrol Exerts Antiproliferative Activity and Induces Apoptosis in Waldenström’s Macroglobulinemia
Aldo M. Roccaro, Xavier Leleu, Antonio Sacco, Anne-Sophie Moreau, Evdoxia Hatjiharissi, Xiaoying Jia, Lian Xu, Bryan Ciccarelli, Christopher J. Patterson, Hai T. Ngo, Domenico Russo, Angelo Vacca, Franco Dammacco, Kenneth C. Anderson, Irene M. Ghobrial, and Steven P. Treon
Clin Cancer Res 2008;14 1849-1858
http://clincancerres.aacrjournals.org/cgi/content/abstract/14/6/1849
Radiation Enhances Adenoviral Gene Therapy in Pancreatic Cancer via Activation of Cytomegalovirus Promoter and Increased Adenovirus Uptake
Takuya Egami, Kenoki Ohuchida, Kazuhiro Mizumoto, Manabu Onimaru, Hiroki Toma, Shoko Nishio, Eishi Nagai, Kunio Matsumoto, Toshikazu Nakamura, and Masao Tanaka
Clin Cancer Res 2008;14 1859-1867
http://clincancerres.aacrjournals.org/cgi/content/abstract/14/6/1859
Inhibition of the Tumor Necrosis Factor- Pathway Is Radioprotective for the Lung
Ming Zhang, Jun Qian, Xianying Xing, Feng-Ming Kong, Lujun Zhao, Ming Chen, and Theodore S. Lawrence
Clin Cancer Res 2008;14 1868-1876
http://clincancerres.aacrjournals.org/cgi/content/abstract/14/6/1868
Ataxia Telangiectasia Mutated and p21CIP1 Modulate Cell Survival of Drug-Induced Senescent Tumor Cells: Implications for Chemotherapy
Elvira Crescenzi, Giuseppe Palumbo, Jasper de Boer, and Hugh J.M. Brady
Clin Cancer Res 2008;14 1877-1887
http://clincancerres.aacrjournals.org/cgi/content/abstract/14/6/1877
Novel Delivery of SN38 Markedly Inhibits Tumor Growth in Xenografts, Including a Camptothecin-11–Refractory Model
Puja Sapra, Hong Zhao, Mary Mehlig, Jennifer Malaby, Patricia Kraft, Clifford Longley, Lee M. Greenberger, and Ivan D. Horak
Clin Cancer Res 2008;14 1888-1896
http://clincancerres.aacrjournals.org/cgi/content/abstract/14/6/1888
Sensitivity of Squamous Cell Carcinoma Lymph Node Metastases to Herpes Oncolytic Therapy
Zhenkun Yu, Sen Li, Yu-Yao Huang, Shu-Fu Lin, Yuman Fong, and Richard J. Wong
Clin Cancer Res 2008;14 1897-1904
http://clincancerres.aacrjournals.org/cgi/content/abstract/14/6/1897
Toll-like Receptor 4 Mediates an Antitumor Host Response Induced by Salmonella choleraesuis
Che-Hsin Lee, Chao-Liang Wu, and Ai-Li Shiau
Clin Cancer Res 2008;14 1905-1912
http://clincancerres.aacrjournals.org/cgi/content/abstract/14/6/1905
——————————————————————————–
Cancer Susceptibility and Prevention
——————————————————————————–
Molecular Alterations in Spontaneous Sputum of Cancer-Free Heavy Smokers: Results from a Large Screening Program
Ekaterina Baryshnikova, Annarita Destro, Maurizio Valentino Infante, Silvio Cavuto, Umberto Cariboni, Marco Alloisio, Giovanni Luca Ceresoli, Romano Lutman, Giorgio Brambilla, Giuseppe Chiesa, Gianni Ravasi, and Massimo Roncalli
Clin Cancer Res 2008;14 1913-1919
http://clincancerres.aacrjournals.org/cgi/content/abstract/14/6/1913
——————————————————————————–
Letters to the Editor
——————————————————————————–
Does Erythropoietin Promote Tumor Growth?
Donghoon Yoon, Neeraj Agarwal, and Josef T. Prchal
Clin Cancer Res 2008;14 1920
http://clincancerres.aacrjournals.org/cgi/content/full/14/6/1920
Does Erythropoietin Promote Tumor Growth?
Pierre Saintigny, Benjamin Besse, Jean-Charles Soria, Jean-François Bernaudin, and Patrice Callard
Clin Cancer Res 2008;14 1920-1921
http://clincancerres.aacrjournals.org/cgi/content/full/14/6/1920-a
The LGBT Cancer Project
17 Mar 2008 | : *News*, Announcements
The LGBT Cancer Project has received several requests from researchers with special interest in LGBT risks and survivorship issues. We support high quality research for our community. If you cannot participate yourself, please forward or post these requests.
1. Cancer Prevention Study-3 (CPS-3)
Developed by The American Cancer Society, the purpose of CPS-3 is to better understand the lifestyle, behavioral, environmental and genetic factors that cause or prevent cancer and to ultimately eliminate cancer as a major health problem for this and future generations. The ultimate goal is to enroll 500,000 adults from various racial/ethnic backgrounds from across the U.S. Men and women between the ages of 30 and 65 years who have no personal history of cancer are invited to join. We are actively reaching out to the LGBT community. Participants will be followed for at least 20 years. You will be contacted every two years with mailed questionnaires to answer. While you may be in the study for many years, we expect the amount of time it will take you to answer a questionnaire to be minimal (about 45 minutes for the follow-ups)
For more information, email cps3@cancer.org or go to
http://www.cancer.org/docroot/RES/RES_6_6.asp?
or call toll-free 1-888-604-5888.
2. Sexual Wellbeing in Breast Cancer Survivors
Researchers at Boston University are seeking lesbian, bisexual women and women who partner with women for a study on sexual wellbeing and breast cancer survivorship. Participants will receive $20 for the completion of a one-time mail survey involving questions about sexual health, physical health and relationship status. At this time, we are enrolling lesbian and bisexual women who have had a breast cancer diagnosis. We are also enrolling lesbian and bisexual women over the age of 40 who have not had a breast cancer diagnosis.
Participation requires 5 minutes for a brief screening interview by phone and approximately 30 minutes to complete a survey; materials are provided for mailing the survey back to Boston University.
For more information, contact Mairead Sullivan at
877-414-1399 or women@bu.edu
3. How Breast Cancer Patients Navigate Fertility Concerns and Treatment Options
Northwestern University’s Department of Sociology invites women who have been diagnosed with or who have had breast cancer to participate in an interview-based study. Participants will be interviewed about their fertility concerns, family life and future family plans. The project will also look at how doctors and patients discuss these issues. The findings will help to develop educational materials for physicians and patients regarding the concerns, experiences and treatment options related to cancer-related infertility among women with breast cancer.
All women between the ages of 18 to 40 with a history of breast cancer are eligible (both pre and post treatment). A key concern of the project is that women from all backgrounds, racial/ethnic groups and sexual orientations are represented.
Participation will involve a 60-90 minute phone interview.
For more information, contact Dr. Karrie Ann Snyder,
karrie-snyder@northwestern.edu or 847/467-0517
.jpg)
